P
Pamela M. Klein
Researcher at Genentech
Publications - 23
Citations - 7016
Pamela M. Klein is an academic researcher from Genentech. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 14, co-authored 21 publications receiving 6653 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Denise A. Yardley,Roohi Ismail-Khan,Bohuslav Melichar,Mikhail Lichinitser,Pamela N. Munster,Pamela M. Klein,Scott Cruickshank,Kathy D. Miller,Min J. Lee,Jane B. Trepel +9 more
TL;DR: A randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane versus exemstane alone in estrogen receptor-positive (ER+) breast cancer patients.
Journal ArticleDOI
Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study
Carmen J. Allegra,Soon Paik,Linda H. Colangelo,Allyson L. Parr,Ilan R. Kirsch,George P. Kim,Pamela M. Klein,Patrick G. Johnston,Norman Wolmark,H. Samuel Wieand +9 more
TL;DR: It is demonstrated that TS, Ki-67, and p53 staining each had significant prognostic value for patients with Dukes' B and C colon carcinoma, but none of the markers could be used to clearly discern groups of individuals who would be predicted to derive greater or lesser benefit from the use of adjuvant chemotherapy.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor
Denise A. Yardley,Roohi Ismail-Khan,Bohuslav Melichar,Mikhail Lichinitser,Pamela N. Munster,Pamela M. Klein,Scott Cruickshank,Kathy D. Miller,Min J. Lee,Jane B. Trepel +9 more
TL;DR: Entinostat added to exemestane is generally well tolerated and demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II study.
Journal ArticleDOI
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
TL;DR: This population pharmacokinetic model can predict trastuzumab exposure in the long-term treatment of patients with metastatic breast cancer and provide comparison of alternative dosage regimens via simulation.